Balogh Gabriela A, Mailo Daniel, Nardi Hector, Corte Maria Marta, Vincent Esteban, Barutta Elena, Lizarraga Guillermo, Lizarraga Pablo, Montero Hector, Gentili Roberto
CERZOS-CONICET, Centro Científico Tecnológico Bahía Blanca, Bahia Blanca-8000, Argentina.
Exp Ther Med. 2010 Mar;1(2):357-361. doi: 10.3892/etm_00000056. Epub 2010 Mar 1.
The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery.
本研究的目的是比较乳腺癌患者血清中抗 p53 抗体水平的敏感性，并将其表达水平与患者年龄、组织学分期和肿瘤分化程度相关联。还使用免疫组织化学（IHC）测定了乳腺癌组织中总 p53 蛋白表达（突变型和野生型）。发现突变型 p53 表达的血清水平与年龄有关，在 50 岁时达到最高水平。在≤30 岁的患者中观察到微弱或低检测率。在≤40 岁和≥61 岁的患者中检测到抗 p53 抗体。突变型 p53 蛋白的血清水平在乳腺癌的所有阶段，包括早期阶段，都有很高的检测率。然而，抗 p53 抗体仅在 III 期乳腺癌中检测率较高。在乳腺良性疾病患者中未发现表达。p53 突变的检测取决于肿瘤分化程度，在低分化乳腺癌中达到最高水平。免疫组织化学结果与血清 p53 突变分析高度相关。我们的研究结果表明，血清中的突变型 p53 是一个有前景的新参数，可用于通过血液样本从早期阶段评估乳腺癌的细胞生物学和预后。在本研究中，抗 p53 抗体的敏感性较低。在手术前，也可以使用突变型 p53 蛋白的表达作为分子标志物来区分乳腺良性疾病和乳腺癌。
